Alpha1-antitrypsin polymorphism in fibromyalgia syndrome patients from the Asturias Province in Northern Spain: A significantly higher prevalence of the PI*Z deficiency allele in patients than in the general population

Journal of Musculoskeletal Pain

Volumn 14, Issue 3, 2006, Pages 5-12

  Blanco, Ignacio ^a   Arbesú, Daxniel ^a   Al Kassam, Daniel ^a   De Serres, Frederick J ^b   Fernández Bustillo, Enrique ^c   Rodríguez, Carmen ^c  

^a HOSPITAL VALLE DEL NALÓN   (Spain)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Alpha1 antitrypsin; Alpha1 antitrypsin allelic polymorphism; Fibromyalgia syndrome; SERPINA1

Indexed keywords

ALPHA 1 ANTITRYPSIN; PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BLOOD LEVEL; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FIBROMYALGIA; GENE FREQUENCY; HUMAN; ISOELECTRIC FOCUSING; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; OUTPATIENT DEPARTMENT; PHENOTYPE; POPULATION; PREVALENCE; PROTEIN POLYMORPHISM; SPAIN;

EID: 33748458840     PISSN: 10582452     EISSN: 15407012     Source Type: Journal    
DOI: 10.1300/J094v14n03_02     Document Type: Article

References (24)

1. American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. Am J Resp Clin Care Med 168: 818-900, 2003.
2. Brantly M: α1-Antitrypsin: Not just an antiprotease. Extending the half-live of a natural anti-inflammatory molecule by conjugation with poliethylene glycol. Am J Respir Cell Mol Biol 27: 652-654, 2002.
3. Spencer LT, Paone G, Krein PM, Rouhani FN, Rivera-Nieves J, Brantly ML: The role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol 286(3): 514-520, 2004.
4. Carrell RW, Lomas DA: Alpha1-antitrypsin deficiency-A model for conformational diseases. N Engl J Med 346(1): 45-53, 2002.
5. de Serres, FJ: Worldwide racial and ethnic distribution of alpha-1-antitrypsin deficiency: Details of an analysis of published genetic epidemiological surveys. Chest 122(5): 1818-1829, 2002.
6. Blanco I, Fernández E, Bustillo EF: Alpha-1-antitrypsin PI phenotypes S and Z in Europe: An analysis of the published surveys. Clin Genet 60(1): 31-41, 2001.
7. Blanco I, Bustillo EF, Rodriguez MC: Distribution of α 1-antitrypsin PIS and PIZ frequencies in countries outside Europe: A meta-analysis. Clin Genet 60 (6): 431-441, 2001.
8. Neumann L, Buskila D: Epidemiology of fibromyalgia. Current Pain and Headache Rep 7(5): 362-368, 2003.
9. Nampiaparampil DE, Shmerling RH: A review of fibromyalgia. Am J Manag Care 11: 794-800, 2004.
10. Carmona L, Ballina J, Gabriel R, Laffton A: EPISER study group. The burden of musculoskeletal diseases in the general population of Spain: Results from a national survey. Ann Rheum Dis 60(11): 1040-1045, 2001.
11. Rao SG, Clauw DJ: The management of fibromyalgia. Drugs of Today 40(6): 539-554, 2004.
12. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH: Cytokines play an aetiopathogenetic role in fibromyalgia: A hypothesis and pilot study. Rheumathology [Oxford] 40(7): 743-749, 2001.
13. Buskila D, Neumann L, Press J: Genetic factors in neuromusclar pain. CNS Spectr 10(4): 281-284, 2005.
14. Blanco I, Canto H, de Serres FJ, Bustillo EF, Rodríguez MC: Alpha-1-antitrypsin replacement therapy efficiently controls fibromyalgia symptoms in two PIZZ alpha-1-antitrypsin deficiency patients. J Rheumatol 31(10): 2082-2085, 2004.
15. Blanco I, de Serres FJ, Fernandez-Bustillo E, et al: Alpha 1-antitrypsin and fibromyalgia: New data in favour of the inflammatory hypothesis of fibromyalgia. Med Hypotheses 64(4): 759-69, 2005.
16. Blanco I, Fernández E, Rodríguez MC, Fernandez A: Allelic frequency of the gene of alpha-1-antitrypsin in the general population in a county in Asturias. Med Clin [Barc] 113(10): 366-370, 1999.
17. Blanco I, Fernández E: α1-antitrypsin Pi phenotypes S and Z in Spain: An analysis of the published surveys. Respir Medicine 95: 109-114, 2001.
18. de Serres FJ, Blanco I, Bustillo EF: Genetic epidemiology of alpha-1 antitrypsin deficiency in Southern Europe: France, Italy, Portugal, and Spain. Clin Genet 63: 1818-1829, 2003.
19. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum 33: 160-172, 1990.
20. Nita I, Hollander C, Westin U, Janciauskiene S: Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir Res 31(1): 12-18, 2005.
21. Stockley RA: Alpha-1 antitrypsin: More than just deficiency. Thorax 59(5): 363-364, 2004.
22. Carrel RW, Lomas DA, Sidhar S, Foreman R: α-Antitrypsin, a conformational disease. Chest 110: 243S-247S, 1996.
23. Aldonyte R, Janson L, Ljungberg O, Larsson S, Janciauskiene S: Polymerized alpha-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of alpha-antitrypsin polymerization. Histopathology 45(6): 587-592, 2004.
24. Mahadeva R, Atkinson C, Li Z, Stewart S, Janciauskiene S, Kelley DG, Parmar J, Pitman R, Shapiro SD, Lomas DA: Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 166(2): 377-386, 2005.